0H7R Stock Chart & Stats
$5.95
$0.26(4.11%)
At close: 4:00 PM EDT
$5.95
$0.26(4.11%)
Day’s Range― - ―
52-Week Range$3.84 - $8.25
Previous CloseN/A
Volume3.00K
Average Volume (3M)4.84K
Market Cap
$246.46M
Enterprise Value$225.61M
Total Cash (Recent Filing)$146.83M
Total Debt (Recent Filing)$19.87M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 16, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend Yield4.59%
Share Statistics
EPS (TTM)-1.14
Shares Outstanding57,184,017
10 Day Avg. Volume9,070
30 Day Avg. Volume4,837
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue8.84
Enterprise Value/Gross Profit15.61
Enterprise Value/Ebitda-3.16
Forecast
1Y Price Target
$22.00Price Target Upside269.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$52.63M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionRising treatment volume and sequential revenue growth show that ZEVASKYN is moving beyond development into early commercial adoption. Continued patient uptake can broaden physician experience, improve operating learning, and support a more durable revenue base as additional treatment centers become productive.
Reimbursement SupportThe NTAP award provides supplemental hospital reimbursement and strengthens the commercial infrastructure supporting ZEVASKYN adoption. As a regulatory and reimbursement milestone, it can reduce payer friction, reinforce the therapy’s clinical value proposition, and support treatment access over multiple quarters.
Liquidity And LeverageA sizable cash and investment balance combined with modest leverage gives Abeona financial flexibility while it expands commercialization. This liquidity can fund treatment-center development and operating needs, while the relatively low debt burden limits fixed repayment pressure during the ongoing transition toward profitability.
Bears Say
Persistent UnprofitabilityAbeona’s commercial progress has not yet translated into sustainable earnings or cash generation. Large operating and free-cash-flow deficits require substantial funding for continued operations, leaving the company exposed to financing dependence unless revenue scales and expenses narrow materially.
Manufacturing Yield RiskManufacturing failures can create a direct gap between patients treated and revenue recognized, while Abeona still absorbs the associated production costs. Repeated yield or specification problems could weaken gross-margin improvement, disrupt patient scheduling, and make the commercial revenue ramp less predictable.
Operational Execution ComplexityThe short product shelf life makes delivery dependent on tightly coordinated biopsy, manufacturing, hospital, and treatment steps. This complexity can constrain throughput as the network grows, increase the risk of canceled or delayed procedures, and slow the conversion of activated centers into recurring revenue.
Abeona Therapeutics News
0H7R FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest share price was $3.84 and its highest was $8.25 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $246.46M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 20 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.118.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 4.59%. See more information on Abeona Therapeutics dividends here
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 57,184,017 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -13.76%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in GB:0H7R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (269.75% Upside)
$22.00 (269.75% Upside)
Blogger Sentiment
Bullish
GB:0H7R Sentiment 92%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth $305.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.35%
12-Months-Change
Fundamentals
Return on Equity
-41.69%
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
0H7R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.View all GB:0H7R earnings summaries0H7R Stock 12 Month Forecast
Average Price Target
$22.00
▲(269.75% Upside)